| Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease S Mudaliar, RR Henry, AJ Sanyal, L Morrow, HU Marschall, M Kipnes, ... Gastroenterology 145 (3), 574-582. e1, 2013 | 1044 | 2013 |
| Comorbid illness is associated with survival and length of hospital stay in patients with chronic disability: a prospective comparison of three comorbidity indices PA Rochon, JN Katz, LA Morrow, R McGlinchey-Berroth, MM Ahlquist, ... Medical care 34 (11), 1093-1101, 1996 | 352 | 1996 |
| Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes RA DeFronzo, M Hompesch, S Kasichayanula, X Liu, Y Hong, M Pfister, ... Diabetes care 36 (10), 3169-3176, 2013 | 347 | 2013 |
| Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes AC Moses, SCJ Young, LA Morrow, M O'Brien, DR Clemmons Diabetes 45 (1), 91-100, 1996 | 347 | 1996 |
| Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin D Devineni, L Morrow, M Hompesch, D Skee, A Vandebosch, J Murphy, ... Diabetes, Obesity and Metabolism 14 (6), 539-545, 2012 | 281 | 2012 |
| Growth factors and angiogenesis. RJ Schott, LA Morrow Cardiovascular research 27 (7), 1155-1161, 1993 | 176 | 1993 |
| Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects A de la Peña, M Riddle, LA Morrow, HH Jiang, H Linnebjerg, A Scott, ... Diabetes care 34 (12), 2496-2501, 2011 | 155 | 2011 |
| Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes A Digenio, RL Dunbar, VJ Alexander, M Hompesch, L Morrow, RG Lee, ... Diabetes care 39 (8), 1408-1415, 2016 | 153 | 2016 |
| Prevalence of mutations in the insulin receptor gene in subjects with features of the type A syndrome of insulin resistance DE Moller, O Cohen, Y Yamaguchi, R Assiz, F Grigorescu, A Eberle, ... Diabetes 43 (2), 247-255, 1994 | 150 | 1994 |
| Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial GR Fulcher, JS Christiansen, G Bantwal, M Polaszewska-Muszynska, ... Diabetes Care 37 (8), 2084-2090, 2014 | 145 | 2014 |
| Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study J Rosenstock, RM Bergenstal, TC Blevins, LA Morrow, MJ Prince, Y Qu, ... Diabetes care 36 (3), 522-528, 2013 | 104 | 2013 |
| Age differences in the plasma clearance mechanisms for epinephrine and norepinephrine in humans LA MORROW, OA LINARES, TJ HILL, JA SANFIELD, MA SUPIANO, ... The Journal of Clinical Endocrinology & Metabolism 65 (3), 508-511, 1987 | 104 | 1987 |
| Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance. LA Morrow, MB O'Brien, DE Moller, JS Flier, AC Moses The Journal of Clinical Endocrinology & Metabolism 79 (1), 205-210, 1994 | 102 | 1994 |
| Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes S Sha, D Devineni, A Ghosh, D Polidori, M Hompesch, S Arnolds, ... PLoS One 9 (8), e105638, 2014 | 90 | 2014 |
| Late-life spinal cord injury and aging with a long term injury: characteristics of two emerging populations R McGlinchey-Berroth, L Morrow, M Ahlquist, M Sarkarati, KL Minaker The journal of spinal cord medicine 18 (3), 183-193, 1995 | 77 | 1995 |
| Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies DJ Nunez, MA Bush, DA Collins, SL McMullen, D Gillmor, G Apseloff, ... PloS one 9 (4), e92494, 2014 | 75 | 2014 |
| Norepinephrine metabolism in humans. Kinetic analysis and model. OA Linares, JA Jacquez, LA Zech, MJ Smith, JA Sanfield, LA Morrow, ... The Journal of clinical investigation 80 (5), 1332-1341, 1987 | 73 | 1987 |
| Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidase L Morrow, DB Muchmore, M Hompesch, EA Ludington, DE Vaughn Diabetes care 36 (2), 273-275, 2013 | 72 | 2013 |
| Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a … P Stein, JK Berg, L Morrow, D Polidori, E Artis, S Rusch, N Vaccaro, ... Metabolism 63 (10), 1296-1303, 2014 | 70 | 2014 |
| Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase M Hompesch, DB Muchmore, L Morrow, DE Vaughn Diabetes care 34 (3), 666-668, 2011 | 69 | 2011 |
